Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis

Ho Yeon Chung,1 Jawon Koo,1 Su Kyoung Kwon,2 Moo-IL Kang,3 Seong-Hwan Moon,4 Jin-Young Park,5 Chan Soo Shin,6 Byung-Koo Yoon,7 Hyun-Koo Yoon,8 Jae-Suk Chang,9 Yoon-Sok Chung,10 Hyoung-Moo Park111Department of Internal Medicine, Kyung Hee University, 2Department of Statistics, 3Department of Internal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chung HY, Koo J, Kwon SK, Kang MI, Moon SH, Park JY, Shin CS, Yoon BK, Yoon HK, Chang JS, Chung YS, Park HM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	bisphosphonate cholecalciferol bone markers 25(OH)D Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/4c79c4956f5a488b9544ba48fcbc6b15
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c79c4956f5a488b9544ba48fcbc6b15
record_format	dspace
spelling	oai:doaj.org-article:4c79c4956f5a488b9544ba48fcbc6b152021-12-02T07:07:29ZEarly changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis1178-1998https://doaj.org/article/4c79c4956f5a488b9544ba48fcbc6b152013-05-01T00:00:00Zhttps://www.dovepress.com/early-changes-in-25-hydroxyvitamin-d-levelsand-bone-markers-after-mont-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ho Yeon Chung,1 Jawon Koo,1 Su Kyoung Kwon,2 Moo-IL Kang,3 Seong-Hwan Moon,4 Jin-Young Park,5 Chan Soo Shin,6 Byung-Koo Yoon,7 Hyun-Koo Yoon,8 Jae-Suk Chang,9 Yoon-Sok Chung,10 Hyoung-Moo Park111Department of Internal Medicine, Kyung Hee University, 2Department of Statistics, 3Department of Internal Medicine, Catholic University of Korea, 4Department of Orthopedics, Yonsei University, 5Department of Orthopedics, Konkuk University, 6Department of Internal Medicine, Seoul National University, 7Department of Obstetrics and Gynecology, Sungkyunkwan University, 8Department of Internal Medicine, Kwandong University, 9Department of Orthopedics, University of Ulsan, Seoul, South Korea; 10Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea; 11Department of Obstetrics and Gynecology, Chung-Ang University, Seoul, South KoreaPurpose: This study investigated the efficacy and safety of monthly risedronate, with and without cholecalciferol, on 25-hydroxyvitamin D (25[OH]D) levels and bone markers in Korean patients with osteoporosis.Methods: A randomized, double-blinded, prospective, 16-week clinical trial was conducted in ten hospitals. A total of 150 subjects with osteoporosis were randomized to one of the two treatment groups: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74) or RSDM (monthly risedronate 150 mg alone, n = 76). We measured serum levels of 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), and bone markers, as well as performing muscle-function tests at baseline and after 16 weeks of treatment.Results: After 16 weeks, serum 25(OH)D levels significantly increased from 17.8 to 26.8 ng/mL in the RSDM+ group, but did not change in the RSDM group. The RSDM+ group exhibited significantly decreased serum PTH from 46 to 36.7 pg/mL, while the RSDM group showed a tendency for PTH to increase from 38 to 40.6 pg/mL. In both groups, serum bone-specific alkaline phosphatase and C-terminal telopeptide rapidly declined, with significance at 16 weeks; there were no significant differences between the groups.Conclusion: A once-monthly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D levels over the 16-week treatment period without significant adverse events in Korean patients with osteoporosis. Keywords: bisphosphonate, cholecalciferol, bone markers, 25(OH)DChung HYKoo JKwon SKKang MIMoon SHPark JYShin CSYoon BKYoon HKChang JSChung YSPark HMDove Medical Pressarticlebisphosphonatecholecalciferolbone markers25(OH)DGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 597-603 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	bisphosphonate cholecalciferol bone markers 25(OH)D Geriatrics RC952-954.6
spellingShingle	bisphosphonate cholecalciferol bone markers 25(OH)D Geriatrics RC952-954.6 Chung HY Koo J Kwon SK Kang MI Moon SH Park JY Shin CS Yoon BK Yoon HK Chang JS Chung YS Park HM Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
description	Ho Yeon Chung,1 Jawon Koo,1 Su Kyoung Kwon,2 Moo-IL Kang,3 Seong-Hwan Moon,4 Jin-Young Park,5 Chan Soo Shin,6 Byung-Koo Yoon,7 Hyun-Koo Yoon,8 Jae-Suk Chang,9 Yoon-Sok Chung,10 Hyoung-Moo Park111Department of Internal Medicine, Kyung Hee University, 2Department of Statistics, 3Department of Internal Medicine, Catholic University of Korea, 4Department of Orthopedics, Yonsei University, 5Department of Orthopedics, Konkuk University, 6Department of Internal Medicine, Seoul National University, 7Department of Obstetrics and Gynecology, Sungkyunkwan University, 8Department of Internal Medicine, Kwandong University, 9Department of Orthopedics, University of Ulsan, Seoul, South Korea; 10Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea; 11Department of Obstetrics and Gynecology, Chung-Ang University, Seoul, South KoreaPurpose: This study investigated the efficacy and safety of monthly risedronate, with and without cholecalciferol, on 25-hydroxyvitamin D (25[OH]D) levels and bone markers in Korean patients with osteoporosis.Methods: A randomized, double-blinded, prospective, 16-week clinical trial was conducted in ten hospitals. A total of 150 subjects with osteoporosis were randomized to one of the two treatment groups: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74) or RSDM (monthly risedronate 150 mg alone, n = 76). We measured serum levels of 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), and bone markers, as well as performing muscle-function tests at baseline and after 16 weeks of treatment.Results: After 16 weeks, serum 25(OH)D levels significantly increased from 17.8 to 26.8 ng/mL in the RSDM+ group, but did not change in the RSDM group. The RSDM+ group exhibited significantly decreased serum PTH from 46 to 36.7 pg/mL, while the RSDM group showed a tendency for PTH to increase from 38 to 40.6 pg/mL. In both groups, serum bone-specific alkaline phosphatase and C-terminal telopeptide rapidly declined, with significance at 16 weeks; there were no significant differences between the groups.Conclusion: A once-monthly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D levels over the 16-week treatment period without significant adverse events in Korean patients with osteoporosis. Keywords: bisphosphonate, cholecalciferol, bone markers, 25(OH)D
format	article
author	Chung HY Koo J Kwon SK Kang MI Moon SH Park JY Shin CS Yoon BK Yoon HK Chang JS Chung YS Park HM
author_facet	Chung HY Koo J Kwon SK Kang MI Moon SH Park JY Shin CS Yoon BK Yoon HK Chang JS Chung YS Park HM
author_sort	Chung HY
title	Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
title_short	Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
title_full	Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
title_fullStr	Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
title_full_unstemmed	Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis
title_sort	early changes in 25-hydroxyvitamin d levelsand bone markers after monthly risedronatewith cholecalciferol in korean patients with osteoporosis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/4c79c4956f5a488b9544ba48fcbc6b15
work_keys_str_mv	AT chunghy earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT kooj earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT kwonsk earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT kangmi earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT moonsh earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT parkjy earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT shincs earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT yoonbk earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT yoonhk earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT changjs earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT chungys earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis AT parkhm earlychangesin25hydroxyvitamindlevelsandbonemarkersaftermonthlyrisedronatewithcholecalciferolinkoreanpatientswithosteoporosis
_version_	1718399567159885824

Early changes in 25-hydroxyvitamin D levelsand bone markers after monthly risedronatewith cholecalciferol in Korean patients with osteoporosis

Ejemplares similares